Abstract: Disclosed relates to novel Pyrimidine annulated derivatives of Formula (I) and the preparation methods of these compounds, and to their use as P2Y12 receptor antagonists in the treatment and/or prevention of thrombosis or related disorders.

Abstract: Disclosed in the present invention are a cannabidiol derivative, a preparation method therefor and an application thereof, particularly an application in preventing and treating nervous system diseases (such as Parkinson's disease). The cannabidiol derivative is obtained by screening from a series of synthetic derivatives. An animal testing result shows that the cannabidiol derivative can reduce the balance beam score of a Parkinson's model animal and improve the dopamine level and the tyrosine hydroxylase (TH) cell positive rate in substantia nigra (SubN), can be used for drug development and research of various diseases such as epilepsy and Parkinson's disease, and has better application value.

Abstract: Provided are anti-ABCB 1 antibodies that may be used as multi-specific, including bispecific, antibodies targeting both ABCB 1 and a tumor-associated antigen (TAA), as well as pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies and multi-specific antibodies. Further included are uses and methods of treating conditions where inhibition of ABCB 1-mediated efflux transport is desirable, such as, cancer or multi-drug resistance mediated by the ABCB1 transporter, e.g., multi-drug resistant cancer. In particular, the disclosure provides humanized multi-specific, e.g. bispecific, IgG (IgG1) antibodies that bind ABCB1 and a TAA. Multi-specific IgG1 antibody molecules are provided with Fc substitutions in at least one of a first and a second heavy chain constant region.

Abstract: The present disclosure provides an anti-hypoxic/anoxic injury use of a magnolol and/or honokiol aromatic ring amino-substituted derivative, and a pharmaceutical composition. The derivative is a compound represented by general formula I or a salt thereof: wherein, R1 and R4 are each independently selected from a C1-C8 hydrocarbyl, R2 and R3 are each independently selected from hydrogen or hydroxyl, and R2 and R3 are not both the hydrogen or hydroxyl; R5 is selected from any one of H, a C1-C12 acyl, a remaining acyl moiety of a single amino acid after condensation of its carboxyl, or a remaining acyl moiety of a polypeptide after condensation of its carboxyl; and R6 is selected from any one of hydrogen or C1-C8 hydrocarbyl. The derivative of the structure shown in general formula I may be solved problems of indirect onset and slow onset and the like of existing anti-hypoxic/anoxic drugs.

Abstract: Disclosed are a cannabidiol derivative, and a preparation method therefor and the use thereof, and in particular the use thereof in the prevention and treatment of a nervous system disease (such as epilepsy and Parkinson's disease). The cannabidiol derivative is obtained by means of screening from a series of synthetic derivatives, and animal test results show that the compounds can effectively shorten the epileptic seizure duration of an experimental animal, improves the epileptic seizure symptoms of the experimental animal, reduces the balance beam score of the Parkinson's model animal, increases the dopamine level and the tyrosine hydroxylase (TH) cell positivity in the substantia nigra (SubN), can be used for drug development and research on various diseases such as epilepsy and Parkinson's disease, and has a better application value.

Abstract: A computer-implemented method for scalable compression of a digital image. The method contains the steps of extracting from the image semantic information at a semantic layer, extracting from the image structure information at a structure layer, extracting from the image signal information at a signal layer; and compressing each one of the semantic information, the structure information, and the signal information into a bitstream. A novel scalable cross-modality image compression is therefore provided where a wide spectrum of novel functionalities have been enabled, making the codec versatile for applications ranging from semantic understanding to signal-level reconstruction.

Abstract: Disclosed is a preparation method for cannflavin compounds. The preparation method has the advantages of cheap and easily available raw materials, few reaction steps, short production period, simple operation, etc. The method comprises: firstly, condensing 4?-hydroxy-3?-methoxyacetophenone and diethyl carbonate (DEC) under an alkaline condition to obtain 4?-hydroxy-3?-methoxybenzoyl acetate; reacting 1,3,5-trihydroxybenzene with bromo-isoamylene under an alkaline condition to obtain 2-isopentenyl-1,3,5-trihydroxybenzene; and finally, condensing 4?-hydroxy-3?-methoxybenzoyl acetate and 2-isopentenyl-1,3,5-trihydroxybenzene at a high temperature to produce cannflavin B and/or isocannflavin B, and then subjecting same to separation and purification to obtain pure cannflavin B and pure isocannflavin B.

Abstract: Disclosed in the present invention is a preparation method for cannflavin compounds. The preparation method has advantages such as cheap and easily available raw materials, few reaction steps, short production period, and easy operation. The method comprises: first, condensing 4?-hydroxy-3?-methoxyacetophenone and diethyl carbonate (DEC) under an alkaline condition to obtain ethyl 4?-hydroxy-3?-methoxybenzoylacetate, next, reacting 1,3,5-trihydroxybenzene with geraniol to obtain (E)-2-(3,7-dimethyloct-2,6-dien-1-yl)benzene-1,3,5-triphenol; and finally, condensing ethyl 4?-hydroxy-3?-methoxybenzoylacetate and (E)-2-(3,7-dimethyloct-2,6-dien-1-yl)benzene-1,3,5-triphenol at high temperature to produce cannflavin A and/or cannflavin C, and then carrying out separation and purification to obtain pure cannflavin A and cannflavin C.

Abstract: The present disclosure provides preparation method for water-soluble magnolol derivatives and honokiol derivatives and intermediates thereof, and related monohydroxy protection intermediates. The nitrification intermediate has a structure shown in Formula I. Formula I is R2 is a hydroxyl, and R3 is H; or, R2 is H, and R3 is a hydroxyl; and R1 and R4 are independently selected from C1˜C12 electron donor groups. The preparation method includes the following steps: performing monohydroxy protection on a compound A with a hydroxy protection reagent in the presence of an acid binding agent to form a monohydroxy protection compound, herein R1, R2, R3 and R4 in the compound A have the same definition as above, and the hydroxy protection reagent is p-toluenesulfonyl chloride and 1-hydroxybenzotriazole; and performing a nitrification reaction and a deprotection reaction on the monohydroxy protection compound successively to obtain the nitrification intermediate.

Abstract: Provided are antibodies that target the cellular efflux pump ABCC1. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCC1 expression in cells, e.g., tumor cells, Level of ABCC1 expression, and/or inhibiting ABCC1 function are also disclosed. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCC1 antibody disclosed herein. The subject antibody may be a bispecific antibody. The bispecific antibody may bind to ABCC1 and a tumor associated antigen (TAA).

Abstract: Provided are antibodies that target the cellular efflux pump ABCG2. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCG2 expression in cells, e.g., tumor cells, level of ABCG2 expression, and/or inhibiting ABCG2 function are also disclosed. In addition, multi-specific antibodies that bind to ABCG2 and a polypeptide expressed on surface of a cancer cell are provided. The polypeptide may be the efflux pump MDR1 or a cancer-associated antigen. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCG2 antibody as disclosed herein or a multi-specific antibody that targets both ABCG2 and a cancer-associated antigen or MDR1.

Abstract: Provided are antibodies that target the cellular efflux pump MDR1. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of MDR1 expression in cells, e.g., tumor cells, level of MDR1 expression, and/or inhibiting MDR1 function are also disclosed. In addition, multi-specific antibodies that bind to MDR1 and a tumor associated antigen are provided. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-MDR1 antibody as disclosed herein or a multi-specific antibody that targets both MDR1 and a tumorassociated antigen.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Abstract: The present application relates to a field of excrement treatment equipment in particular, relates to an ultra-high temperature excrement solid-liquid separation extrusion sterilization integrated machine. It includes a solid-liquid separator, a workbench and an extrusion sterilization device. The solid-liquid separator is disposed on the workbench. The extrusion sterilization device includes an extrusion sterilization motor, an extrusion feeding assembly, a receiving pipe, a receiving box and a dehydrating cage.

Abstract: The present application relates to a field of excrement treatment equipment in particular, relates to an ultra-high temperature excrement solid-liquid separation extrusion sterilization integrated machine. It includes a solid-liquid separator, a workbench and an extrusion sterilization device. The solid-liquid separator is disposed on the workbench. The extrusion sterilization device includes an extrusion sterilization motor, an extrusion feeding assembly, a receiving pipe, a receiving box and a dehydrating cage.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Abstract: In a convolutional neural network (CNN) using an encoder-decoder structure for image segmentation, a multi-scale context aggregation module receives an encoded final-stage feature map from the encoder, and sequentially aggregates multi-scale contexts of this feature map from a global scale to a local scale to strengthen semantic relationships of contexts of different scales to improve segmentation accuracy. The multi-scale contexts are obtained by computing atrous convolution on the feature map for different dilation rates. To reduce computation, a channel-wise feature selection (CFS) module is used in the decoder to merge two input feature maps. Each feature map is processed by a global pooling layer followed by a fully connected layer or a 1×1 convolutional layer to select channels of high activation. By subsequent channel-wise multiplication and elementwise summation, only channels with high activation in both feature maps are preserved and enhanced in the merged feature map.

Abstract: In a convolutional neural network (CNN) using an encoder-decoder structure for image segmentation, a multi-scale context aggregation module receives an encoded final-stage feature map from the encoder, and sequentially aggregates multi-scale contexts of this feature map from a global scale to a local scale to strengthen semantic relationships of contexts of different scales to improve segmentation accuracy. The multi-scale contexts are obtained by computing atrous convolution on the feature map for different dilation rates. To reduce computation required by the CNN, a channel-wise feature selection (CFS) module is used in the decoder to merge two input feature maps. Each feature map is processed by a global pooling layer followed by a fully connected layer or a 1×1 convolutional layer to select channels of high activation. By subsequent channel-wise multiplication and elementwise summation, only channels with high activation in both feature maps are preserved and enhanced in the merged feature map.

Abstract: Embodiments are disclosed of an apparatus including a vehicle. A battery pack including one or more individual batteries powers the vehicle. An underbody shield positioned on the underside of the vehicle protects the battery pack and has integrated therein an induction coil and one or more power conditioning components electrically coupled between the induction coil and the battery pack.

Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.